Seek­ing a place among gi­ants in the on­colyt­ic virus field, lit­tle Cold Genesys bags $22M Se­ries C

A small biotech out of Cal­i­for­nia has re­fu­eled with $22 mil­lion for the next leg of its quest in on­colyt­ic im­munother­a­pies, a hot field that’s grabbed the at­ten­tion of ma­jor phar­ma play­ers keen to find the win­ning com­bo tech in the I/O 2.0 race.

Cold Genesys and its in­vestors for the Se­ries C are pret­ty much putting all their eggs in the CG0070 bas­ket. The com­pa­ny bought the drug, which had al­ready gone through Phase I, from BioSante Phar­ma­ceu­ti­cals back when it first got start­ed in 2010, with $95,000 up­front and a 20% stock own­er­ship. Fast for­ward nine years, CG0070 has been test­ed in more than 100 blad­der can­cer pa­tients in a Phase II as a monother­a­py, and is lined up for com­bi­na­tion tri­als with Mer­ck’s Keytru­da as well as oth­er check­point mod­u­la­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER